Clinical utility of plasma microbial cell-free DNA sequencing for early diagnosis of toxoplasmosis in high-risk patients: a five-patient case series

2026/01/01 by Fernando H. Centeno, Todd Lasco, Mayar Al Mohajer · 1 voice
Immunology and Microbiology · Medicine · #Fungal Infections and Studies #Leptospirosis research and findings #Toxoplasma gondii Research Studies

paper · pdf · doi:10.1017/ash.2026.10382

openalex publication_date 2026/01/01 · openalex created_date 2026/05/12 · openalex updated_date 2026/07/08

Abstract

From 2017 to 2025, we reviewed plasma microbial cell-free DNA sequencing (mcfDNA NGS) results detecting Toxoplasma gondii. Five patients were identified. Median turnaround was 3 days (2-5). mcfDNA initiated therapy in two and supported empiric treatment in three but required clinical context for interpretation.

Discussions

• In a 7-year case series of high-risk patients, plasma microbial cell-free DNA sequencing identified Toxoplasma with 3-day turnaround. Results initiated or supported therapy in all cases, highlighting [bsky, 0 points, 0 comments]

Related

• Diagnosis of histoplasmosis by next-generation sequencing of microbial cell-free DNA in Texas
• Comparative diagnostic performance of plasma microbial cell-free DNA sequencing versus amplicon-based blood next-generation sequencing in suspected bloodstream or endovascular infection: a single-center study
• Plasma Microbial Cell-free DNA Metagenomic Sequencing for Diagnosis of Invasive Fungal Diseases Among High-risk Outpatient and Inpatient Immunocompromised Hosts
• Utility of microbial cell-free DNA sequencing in the diagnosis of mycobacterial infections in a quaternary care center
• Impact of Metagenomic Next-Generation Sequencing of Plasma Cell-free DNA Testing in the Management of Patients With Suspected Infectious Diseases